TCL Archive NCI Grant Funding: “Zone of Likelihood” Moves From 7th to 9th Percentile November 30, 2012
TCL Archive Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study December 26, 2014